Metraipolis › archive › dc_f6173350f2be

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a… — Europe PMC PMID:41407433

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41407433
DOI
10.1136/rmdopen-2025-006333
License (as archived)
solo-consultazione
Archived
2026-11-07T14:07:05.391Z
SHA-256 of the archived text
aa8c509464a2911f63d16bc9bda6645bf48e3d24377eda8e7d0a062aed001379
Stable URL of this page
https://metraipolis.com/documento/dc_f6173350f2be

How to cite

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a… — Europe PMC PMID:41407433 — Europe PMC (en), https://europepmc.org/article/MED/41407433 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f6173350f2be (Metraipolis archive dc_f6173350f2be, sha256 aa8c509464a2911f63d16bc9bda6645bf48e3d24377eda8e7d0a062aed001379)
BibTeX
@misc{dcf6173350f2be,
  title = {Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a… — Europe PMC PMID:41407433},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41407433},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f6173350f2be; sha256 aa8c509464a2911f63d16bc9bda6645bf48e3d24377eda8e7d0a062aed001379},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41407433. Agents can read the archived copy with the MCP tool read_document.